Payment overview · 2025
General Payments
$1,196.56
68 reported records · 26 companies
Healthcare provider profile · identity verified
Craig Barker, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1720059611
Verified facts
What the public records show
CMS Open Payments records show Craig Barker, MD received $1,196.56 in general payments during 2025 across 68 reported records.
ABBVIE INC. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.75 | 12.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.18 | 11.7% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.30 | 8.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.14 | 7.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.96 | 5.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.53 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.31 | 4.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.21 | 4.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.69 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.07 | 3.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.67 | 3.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.64 | 3.4% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $36.14 | 3.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.18 | 2.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.20 | 2.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.81 | 2.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.81 | 2.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.78 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.89 | 1.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.46 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.19 | 1.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.10 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.44 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.50 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.23 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,196.56 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.90 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.90 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.90 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.49 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.49 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.50 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.50 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.96 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.53 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $55.68 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $55.68 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $43.65 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.58 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 145 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 459 | 67 |
| Gabapentin | Gabapentin | 323 | 79 |
| Alprazolam | Alprazolam | 260 | 62 |
| Lisinopril | Lisinopril | 214 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 58 |
| Metformin Hcl | Metformin Hcl | 195 | 63 |
| Tramadol Hcl | Tramadol Hcl | 192 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 45 |
| Losartan Potassium | Losartan Potassium | 161 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 40 |
| Clonazepam | Clonazepam | 129 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 44 |
| Carvedilol | Carvedilol | 121 | 28 |
| Omeprazole | Omeprazole | 113 | 39 |
| Ozempic | Semaglutide | 111 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 33 |
| Allopurinol | Allopurinol | 104 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 31 |
| Furosemide | Furosemide | 97 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 33 |
| Montelukast Sodium | Montelukast Sodium | 85 | 25 |
| Meloxicam | Meloxicam | 81 | 36 |
| Potassium Chloride | Potassium Chloride | 81 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 18 |
| Mounjaro | Tirzepatide | 76 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 20 |
| Simvastatin | Simvastatin | 70 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 16 |
| Aripiprazole | Aripiprazole | 65 | 15 |
| Armour Thyroid | Thyroid,pork | 65 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 14 |
| Famotidine | Famotidine | 62 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 12 |
| Linzess | Linaclotide | 56 | 11 |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 13 |
| Celecoxib | Celecoxib | 49 | 16 |
| Pregabalin | Pregabalin | 48 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Trazodone Hcl | Trazodone Hcl | 47 | 12 |
| Eliquis | Apixaban | 46 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 13 |
| Estradiol | Estradiol | 44 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 15 |
| Valsartan | Valsartan | 40 | 14 |
| Alendronate Sodium | Alendronate Sodium | 39 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 16 |
| Memantine Hcl | Memantine Hcl | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 13 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Buprenorphine | Buprenorphine | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Np Thyroid | Thyroid,pork | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Promethegan | Promethazine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,196.56 · 68 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, Fluad, Flucelvax, GEMTESA, HETLIOZ, IBSRELA, JARDIANCE, Kerendia, Korlym, LINZESS, Leqembi, MOUNJARO, NP Thyroid 60, NUPLAZID, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error